ECSP14000357A - Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes - Google Patents

Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes

Info

Publication number
ECSP14000357A
ECSP14000357A ECIEPI2014357A ECPI201400357A ECSP14000357A EC SP14000357 A ECSP14000357 A EC SP14000357A EC IEPI2014357 A ECIEPI2014357 A EC IEPI2014357A EC PI201400357 A ECPI201400357 A EC PI201400357A EC SP14000357 A ECSP14000357 A EC SP14000357A
Authority
EC
Ecuador
Prior art keywords
pirid
carbamoil
ilo
tetrahydroisoquinoline
immune
Prior art date
Application number
ECIEPI2014357A
Other languages
English (en)
Inventor
Brake Co Ltd Sangsin
Laboratories Limited Mylan
Carlos Ruiz Cuenca José
Bionutrition Corp Advanced
Tax Llc Andersen
Presto Products Inc Reynolds
Nature's Bounty Co The
Aaron R Kunzer
Anonima Vichy Catalan Sociedad
Morse Llc Fairbanks
Music Inc Chicago
Limited Sabmiller
Oil Products Inc Lucas
Original Assignee
Potisek Stephanie L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47116421&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14000357(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Potisek Stephanie L filed Critical Potisek Stephanie L
Publication of ECSP14000357A publication Critical patent/ECSP14000357A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos que inhiben la actividad de las proteínas antiapoptóticas Bcl-xL, composiciones que contienen dichos compuestos y métodos para tratar enfermedades en las que se expresan las proteínas antiapoptóticas Bcl-xL.
ECIEPI2014357A 2011-10-14 2014-05-08 Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes ECSP14000357A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161547162P 2011-10-14 2011-10-14
CN2012079012 2012-07-23

Publications (1)

Publication Number Publication Date
ECSP14000357A true ECSP14000357A (es) 2015-11-30

Family

ID=47116421

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI2014357A ECSP14000357A (es) 2011-10-14 2014-05-08 Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes

Country Status (36)

Country Link
EP (1) EP2766361B1 (es)
JP (2) JP6155270B2 (es)
KR (1) KR102019643B1 (es)
AR (1) AR088327A1 (es)
AU (2) AU2012322698A1 (es)
BR (1) BR112014009053B1 (es)
CA (1) CA2851364C (es)
CL (1) CL2014000905A1 (es)
CO (1) CO6950476A2 (es)
CR (2) CR20200097A (es)
CY (1) CY1118224T1 (es)
DK (1) DK2766361T3 (es)
DO (2) DOP2014000070A (es)
EC (1) ECSP14000357A (es)
ES (1) ES2598877T3 (es)
GT (1) GT201400064A (es)
HK (1) HK1200167A1 (es)
HR (1) HRP20161319T1 (es)
HU (1) HUE030589T2 (es)
IL (1) IL231856A (es)
LT (1) LT2766361T (es)
ME (1) ME02514B (es)
MX (1) MX356031B (es)
PE (1) PE20141282A1 (es)
PH (1) PH12015501498A1 (es)
PL (1) PL2766361T3 (es)
PT (1) PT2766361T (es)
RS (1) RS55342B1 (es)
RU (1) RU2625315C2 (es)
SG (1) SG11201401279XA (es)
SI (1) SI2766361T1 (es)
TW (1) TWI571466B (es)
UA (1) UA115042C2 (es)
UY (1) UY34382A (es)
WO (1) WO2013055897A1 (es)
ZA (1) ZA201402556B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI561521B (en) * 2011-10-14 2016-12-11 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN103987711B (zh) 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
CN111620861A (zh) * 2014-12-09 2020-09-04 艾伯维公司 具有低细胞渗透性的bcl-xl抑制性化合物以及包括它的抗体药物缀合物
CN107249643A (zh) * 2014-12-09 2017-10-13 艾伯维公司 具有细胞渗透性的bcl‑xl抑制剂的抗体药物缀合物
WO2016094517A1 (en) * 2014-12-09 2016-06-16 Abbvie Inc. Bcl-xl inhibitory compounds and antibody drug conjugates including the same
CN104473923B (zh) * 2014-12-29 2016-08-17 巩春智 一种防治慢性心力衰竭的药物组合物及其应用
WO2016131100A1 (en) * 2015-02-18 2016-08-25 The Walter And Eliza Hall Institute Of Medical Research Methods of treating infectious diseases
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
CN116173232A (zh) * 2016-06-08 2023-05-30 艾伯维公司 抗cd98抗体及抗体药物偶联物
CA3027045A1 (en) * 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
CN109600993A (zh) * 2016-06-08 2019-04-09 艾伯维公司 抗egfr抗体药物偶联物
JP2019522643A (ja) * 2016-06-08 2019-08-15 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
BR112018075636A2 (pt) * 2016-06-08 2019-04-09 Abbvie Inc. conjugados de anticorpo fármaco anti-egfr
AU2017277914A1 (en) * 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
CA3027181A1 (en) * 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
WO2018092064A1 (en) * 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
AR119494A1 (es) * 2019-07-29 2021-12-22 Servier Lab DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS
CA3198996A1 (en) 2020-11-24 2022-06-02 Matthew T. Burger Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN117794929A (zh) 2021-02-02 2024-03-29 法国施维雅药厂 选择性bcl-xl protac化合物及使用方法
WO2023215449A1 (en) * 2022-05-06 2023-11-09 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
US20240238423A9 (en) * 2022-05-06 2024-07-18 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
TW202408588A (zh) 2022-05-20 2024-03-01 瑞士商諾華公司 抗體-藥物結合物抗腫瘤化合物及其使用方法
AR129382A1 (es) 2022-05-20 2024-08-21 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de bcl-xl y met y sus métodos de uso
WO2023236814A1 (zh) * 2022-06-10 2023-12-14 成都先导药物开发股份有限公司 一种化合物及其在制备bcl-xl抑制剂中的用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
ATE257829T1 (de) 1995-09-15 2004-01-15 Upjohn Co Aminoaryl oxazolidinone n-oxide
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
MXPA02012596A (es) * 2000-06-21 2003-04-10 Hoffmann La Roche Derivados de benzotiazol.
CA2508947A1 (en) 2002-12-20 2004-07-15 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE602004009344T2 (de) 2004-04-19 2008-07-10 Symed Labs Ltd., Hyderabad Neues verfahren zur herstellung von linezolid und verwandten verbindungen
ATE429423T1 (de) 2004-07-20 2009-05-15 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
WO2008131259A1 (en) 2007-04-19 2008-10-30 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
JP2010540635A (ja) 2007-10-02 2010-12-24 コンサート ファーマシューティカルズ インコーポレイテッド ピリミジンジオン誘導体
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
CA2703591C (en) 2007-10-26 2013-05-07 Concert Pharmaceuticals, Inc. Deuterated darunavir
KR101633532B1 (ko) * 2008-12-19 2016-06-24 제넨테크, 인크. 화합물 및 사용 방법
BRPI0918360A8 (pt) * 2008-12-19 2017-12-05 Genentech Inc Composto, composição farmacêutica e usos de um composto
KR20110123657A (ko) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
TWI561521B (en) * 2011-10-14 2016-12-11 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Also Published As

Publication number Publication date
EP2766361A1 (en) 2014-08-20
CY1118224T1 (el) 2017-06-28
TW201319064A (zh) 2013-05-16
UA115042C2 (uk) 2017-09-11
IL231856A0 (en) 2014-05-28
AU2017206246A1 (en) 2017-08-10
JP6155270B2 (ja) 2017-06-28
ME02514B (me) 2017-02-20
RS55342B1 (sr) 2017-03-31
RU2014119250A (ru) 2015-11-20
CR20140205A (es) 2014-07-17
LT2766361T (lt) 2016-11-10
TWI571466B (zh) 2017-02-21
SG11201401279XA (en) 2014-05-29
HUE030589T2 (en) 2017-05-29
ES2598877T3 (es) 2017-01-30
GT201400064A (es) 2014-12-23
EP2766361B1 (en) 2016-08-10
PL2766361T3 (pl) 2017-03-31
ZA201402556B (en) 2017-09-27
CO6950476A2 (es) 2014-05-20
MX2014004556A (es) 2014-07-09
PE20141282A1 (es) 2014-10-26
AU2012322698A1 (en) 2014-04-17
NZ623100A (en) 2016-04-29
KR20140075793A (ko) 2014-06-19
BR112014009053B1 (pt) 2022-03-29
WO2013055897A1 (en) 2013-04-18
JP2014530238A (ja) 2014-11-17
SI2766361T1 (sl) 2016-11-30
IL231856A (en) 2017-07-31
DOP2014000070A (es) 2014-07-31
AR088327A1 (es) 2014-05-28
PH12015501498B1 (en) 2015-12-14
CL2014000905A1 (es) 2014-09-22
BR112014009053A2 (pt) 2017-06-13
RU2625315C2 (ru) 2017-07-13
JP2017197530A (ja) 2017-11-02
DOP2019000022A (es) 2019-02-15
AU2017206246B2 (en) 2018-07-26
HK1200167A1 (zh) 2015-07-31
HRP20161319T1 (hr) 2016-12-16
CR20200097A (es) 2020-03-31
UY34382A (es) 2013-05-31
KR102019643B1 (ko) 2019-09-10
PH12015501498A1 (en) 2015-12-14
MX356031B (es) 2018-05-09
CA2851364C (en) 2020-03-10
CA2851364A1 (en) 2013-04-18
DK2766361T3 (en) 2016-12-05
PT2766361T (pt) 2016-10-27
JP6395893B2 (ja) 2018-09-26

Similar Documents

Publication Publication Date Title
ECSP14000357A (es) Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
DOP2018000026A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
DOP2017000186A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
ECSP14000606A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
GT201400066A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO6640274A2 (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
CO2017011851A2 (es) Compuestos novedosos
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
UY33047A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
ECSP12012017A (es) DERIVADOS DE SULFONAMIDA COMO AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CÁNCER Y ENFERMEDADES INMUNES
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
CR20110351A (es) Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cáncer y enfermedades inmunes
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CO6571908A2 (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedaded inmunes y autoinmunes
PE20151023A1 (es) Triazolopirazinas
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
ECSP14030779A (es) Inhibidores del nampt
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
AR092736A1 (es) Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf-r
UY35600A (es) "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas"